437 related articles for article (PubMed ID: 24925721)
21. Kindlin-2 Association with Rho GDP-Dissociation Inhibitor
Sun Y; Guo C; Ma P; Lai Y; Yang F; Cai J; Cheng Z; Zhang K; Liu Z; Tian Y; Sheng Y; Tian R; Deng Y; Xiao G; Wu C
J Am Soc Nephrol; 2017 Dec; 28(12):3545-3562. PubMed ID: 28775002
[TBL] [Abstract][Full Text] [Related]
22. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
23. HIV-associated nephropathy: experimental models.
Avila-Casado C; Fortoul TI; Chugh SS
Contrib Nephrol; 2011; 169():270-285. PubMed ID: 21252526
[TBL] [Abstract][Full Text] [Related]
24. Fn14 in podocytes and proteinuric kidney disease.
Sanchez-Niño MD; Poveda J; Sanz AB; Mezzano S; Carrasco S; Fernandez-Fernandez B; Burkly LC; Nair V; Kretzler M; Hodgin JB; Ruiz-Ortega M; Selgas R; Egido J; Ortiz A
Biochim Biophys Acta; 2013 Dec; 1832(12):2232-43. PubMed ID: 23999007
[TBL] [Abstract][Full Text] [Related]
25. SMPDL3b modulates radiation-induced DNA damage response in renal podocytes.
Francis M; Ahmad A; Bodgi L; Azzam P; Youssef T; Abou Daher A; Eid AA; Fornoni A; Pollack A; Marples B; Zeidan YH
FASEB J; 2022 Oct; 36(10):e22545. PubMed ID: 36094323
[TBL] [Abstract][Full Text] [Related]
26. Podocyte-specific loss of Cdc42 leads to congenital nephropathy.
Scott RP; Hawley SP; Ruston J; Du J; Brakebusch C; Jones N; Pawson T
J Am Soc Nephrol; 2012 Jul; 23(7):1149-54. PubMed ID: 22518006
[TBL] [Abstract][Full Text] [Related]
27. 1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.
Ma J; Zhang B; Liu S; Xie S; Yang Y; Ma J; Deng Y; Wang W; Xu L; Li R; Zhang L; Yu C; Shi W
PLoS One; 2013; 8(5):e64912. PubMed ID: 23741418
[TBL] [Abstract][Full Text] [Related]
28. Circulating permeability factor suPAR: from concept to discovery to clinic.
Reiser J
Trans Am Clin Climatol Assoc; 2013; 124():133-8. PubMed ID: 23874017
[TBL] [Abstract][Full Text] [Related]
29. Tyro3 is a podocyte protective factor in glomerular disease.
Zhong F; Chen Z; Zhang L; Xie Y; Nair V; Ju W; Kretzler M; Nelson RG; Li Z; Chen H; Wang Y; Zhang A; Lee K; Liu Z; He JC
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429374
[TBL] [Abstract][Full Text] [Related]
30. Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Egerman MA; Wong JS; Runxia T; Mosoyan G; Chauhan K; Reyes-Bahamonde J; Anandakrishnan N; Wong NJ; Bagiella E; Salem F; Meliambro K; Li H; Azeloglu EU; Coca SG; Campbell KN; Raij L
FASEB J; 2020 Dec; 34(12):16191-16204. PubMed ID: 33070369
[TBL] [Abstract][Full Text] [Related]
31. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus.
Veron D; Villegas G; Aggarwal PK; Bertuccio C; Jimenez J; Velazquez H; Reidy K; Abrahamson DR; Moeckel G; Kashgarian M; Tufro A
PLoS One; 2012; 7(7):e40589. PubMed ID: 22808199
[TBL] [Abstract][Full Text] [Related]
32. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
33. Adrenomedullin ameliorates podocyte injury induced by puromycin aminonucleoside in vitro and in vivo through modulation of Rho GTPases.
Dong N; Meng L; Xue R; Yu M; Zhao Z; Liu X
Int Urol Nephrol; 2017 Aug; 49(8):1489-1506. PubMed ID: 28528353
[TBL] [Abstract][Full Text] [Related]
34. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
Raij L; Tian R; Wong JS; He JC; Campbell KN
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
[TBL] [Abstract][Full Text] [Related]
35. A tripartite complex of suPAR, APOL1 risk variants and α
Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
[TBL] [Abstract][Full Text] [Related]
36. Soluble RARRES1 induces podocyte apoptosis to promote glomerular disease progression.
Chen A; Feng Y; Lai H; Ju W; Li Z; Li Y; Wang A; Hong Q; Zhong F; Wei C; Fu J; Guan T; Liu B; Kretzler M; Lee K; He JC
J Clin Invest; 2020 Oct; 130(10):5523-5535. PubMed ID: 32634130
[TBL] [Abstract][Full Text] [Related]
37. Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease.
Jiang W; Gan C; Zhou X; Yang Q; Chen D; Xiao H; Dai L; Chen Y; Wang M; Yang H; Li Q
Cardiovasc Diabetol; 2023 Oct; 22(1):293. PubMed ID: 37891556
[TBL] [Abstract][Full Text] [Related]
38. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
39. Lipid biology of the podocyte--new perspectives offer new opportunities.
Fornoni A; Merscher S; Kopp JB
Nat Rev Nephrol; 2014 Jul; 10(7):379-88. PubMed ID: 24861084
[TBL] [Abstract][Full Text] [Related]
40. Rac1 GTPase Inhibition Blocked Podocyte Injury and Glomerular Sclerosis during Hyperhomocysteinemia via Suppression of Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation.
Zhang Q; Conley SM; Li G; Yuan X; Li PL
Kidney Blood Press Res; 2019; 44(4):513-532. PubMed ID: 31266025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
